Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C38H41BrN2O6 |
Molecular Weight | 701.646 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=CC=C(OC4=C(OC)C=CC(C[C@]5([H])N(C)CCC6=C(Br)C(OC)=C(OC)C(OC7=C(OC)C=C(CCN1C)C2=C7)=C56)=C4)C=C3
InChI
InChIKey=ANJMFZGRGHQXMA-VMPREFPWSA-N
InChI=1S/C38H41BrN2O6/c1-40-15-13-24-20-31(43-4)33-21-27(24)28(40)17-22-7-10-25(11-8-22)46-32-19-23(9-12-30(32)42-3)18-29-34-26(14-16-41(29)2)35(39)37(44-5)38(45-6)36(34)47-33/h7-12,19-21,28-29H,13-18H2,1-6H3/t28-,29-/m0/s1
Molecular Formula | C38H41BrN2O6 |
Molecular Weight | 701.646 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:53:55 GMT 2023
by
admin
on
Sat Dec 16 16:53:55 GMT 2023
|
Record UNII |
V3ORV27YJY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
62067-29-2
Created by
admin on Sat Dec 16 16:53:55 GMT 2023 , Edited by admin on Sat Dec 16 16:53:55 GMT 2023
|
PRIMARY | |||
|
DTXSID901026509
Created by
admin on Sat Dec 16 16:53:55 GMT 2023 , Edited by admin on Sat Dec 16 16:53:55 GMT 2023
|
PRIMARY | |||
|
V3ORV27YJY
Created by
admin on Sat Dec 16 16:53:55 GMT 2023 , Edited by admin on Sat Dec 16 16:53:55 GMT 2023
|
PRIMARY | |||
|
9831563
Created by
admin on Sat Dec 16 16:53:55 GMT 2023 , Edited by admin on Sat Dec 16 16:53:55 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
5-Bromotetrandrine (BrTet) was shown to overcome multi-drug resistance (MDR) in vitro and in vivo by inhibiting the overexpression and efflux function of P-glycoprotein in our previous study. The cells were treated with non-toxic concentrations of BrTet (1 microM, 2 microM, 4 microM) or the positive control drug verapamil (Vrp) (10 microM) for 24h followed by a low dose Dox (3 microM) for 24 h. The results showed that BrTet pretreatment followed by Dox led to typical apoptotic characters as indicated by morphologic changes, DNA fragmentation and changes in cell cycle, while the same dose of BrTet, Vrp and Dox alone did not induce apoptosis in Bel7402 cells.
|